Lund­beck reads last rites on an­oth­er failed PhI­II Alzheimer’s pro­gram

Lund­beck and Ot­su­ka have racked up two more Phase III flops for their 5-HT6 an­tag­o­nist idalopir­dine, set­ting up cor­po­rate last rites for yet an­oth­er failed Alzheimer’s drug.

The Dan­ish biotech said in their Q4 roundup to­day that “the ef­fi­ca­cy pro­file with idalopir­dine ob­served in these stud­ies and in the (first) STARSHINE study do not demon­strate ef­fi­ca­cy to sup­port a reg­u­la­to­ry sub­mis­sion.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER